X

Create an account to continue reading.

Registered readers have access to our blogs and a limited number of magazine articles
For unlimited access to The Spectator, subscribe below

Registered readers have access to our blogs and a limited number of magazine articles

Sign in to continue

Already have an account?

What's my subscriber number?

Subscribe now from £1 a week

Online

Unlimited access to The Spectator including the full archive from 1828

Print

Weekly delivery of the magazine

App

Phone & tablet edition of the magazine

Spectator Club

Subscriber-only offers, events and discounts
 
View subscription offers

Already a subscriber?

or

Subscribe now for unlimited access

ALL FROM JUST £1 A WEEK

View subscription offers

Thank you for creating your account – To update your details click here to manage your account

Thank you for creating your account – To update your details click here to manage your account

Thank you for creating an account – Your subscriber number was not recognised though. To link your subscription visit the My Account page

Thank you for creating your account – To update your details click here to manage your account

X

Login

Don't have an account? Sign up
X

Subscription expired

Your subscription has expired. Please go to My Account to renew it or view subscription offers.

X

Forgot Password

Please check your email

If the email address you entered is associated with a web account on our system, you will receive an email from us with instructions for resetting your password.

If you don't receive this email, please check your junk mail folder.

X

It's time to subscribe.

You've read all your free Spectator magazine articles for this month.

Subscribe now for unlimited access – from just £1 a week

You've read all your free Spectator magazine articles for this month.

Subscribe now for unlimited access

Online

Unlimited access to The Spectator including the full archive from 1828

Print

Weekly delivery of the magazine

App

Phone & tablet edition of the magazine

Spectator Club

Subscriber-only offers, events and discounts
X

Sign up

What's my subscriber number? Already have an account?

Thank you for creating your account – To update your details click here to manage your account

Thank you for creating your account – To update your details click here to manage your account

Thank you for creating an account – Your subscriber number was not recognised though. To link your subscription visit the My Account page

Thank you for creating your account – To update your details click here to manage your account

X

Your subscriber number is the 8 digit number printed above your name on the address sheet sent with your magazine each week.

Entering your subscriber number will enable full access to all magazine articles on the site.

If you cannot find your subscriber number then please contact us on customerhelp@subscriptions.co.uk or call 0330 333 0050.

You can create an account in the meantime and link your subscription at a later time. Simply visit the My Account page, enter your subscriber number in the relevant field and click 'submit changes'.

Please note: Previously subscribers used a 'WebID' to log into the website. Your subscriber number is not the same as the WebID. Please ensure you use the subscriber number when you link your subscription.

Coffee House

Pfizer’s already beaten Ed Miliband. Now it just needs to offer the right price

6 May 2014

4:52 PM

6 May 2014

4:52 PM

Pfizer will almost certainly have to offer more than its second bid of £50 a share for rival drug giant AstraZeneca, but the American predator seems to be winning the game of spin so far. For a start, Pfizer chief Ian Read turns out to be a Scottish-born graduate of Imperial College London who has spent his entire career with the company. AstraZeneca, by contrast, is run by a Frenchman, Pascal Soriot, under a Swedish chairman, Leif Johansson, both parachuted in two years ago – reminders that Astra Zeneca is already a multinational with its research facilities divided between Cheshire and Sweden and less than 15 per cent of its workforce based in the UK, and that it has recently recovered from a period of underperformance that provoked the departure of its previous top team.

Ed Miliband’s verbiage about the need for powers to block bids that threaten ‘British jobs and science’ already looks like what it is: opportunism that reveals ignorance and antipathy towards business. Read’s reassurance to David Cameron of ‘long-term commitment to the UK’ may not be worth much as the winds of globalisation blow, but the attractiveness of the UK as a tax base for what could be the world’s largest research-based pharmaceutical group is evidently a cause for celebration for George Osborne.

Former AstraZeneca chief executive Sir David Barnes has called Pfizer a ‘praying mantis’ that will ‘suck the lifeblood’ out of his old company, but a more significant voice is that of the doyen of the industry, former GlaxoSmithKline head Sir Richard Sykes, who says ‘ownership is irrelevant’ so long as there’s every encouragement for such companies to ‘do their drug discovery and development here’. In short, the game is Pfizer’s for the taking, when the price is right.

GoveThis is an extract from Martin Vander Weyer’s Any Other Business column in next week’s magazine. Click here to read for free with a trial of The Spectator app for iPad and iPhone. You can also subscribe with a free trial on the Kindle Fire.


Show comments
Close